Companies / BOC Sciences / CFG920
BOC Sciences

CFG920 | BOC Sciences

CFG920 is a Steroid 17-alpha-hydroxylase inhibitor originated by Novartis. It has potential antiandrogen and antineoplastic activities. It may inhibit cell proliferation of androgen-dependent tumor cells. In Jan 2013, Phase-I clinical trials in Prostate cancer in Spain was on-going, but now clinical trials for Prostate cancer is discontinued.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.